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Abstract The elderly population can be divided into three
distinct age groups: 65–74 years (young-old), 75–84 years
(middle-old), and 85? years (old-old). Despite evidence of
a shift in leading causes for mortality in the elderly from
infectious diseases to chronic conditions, infections are still
a serious cause of death in this population. These patients
are at increased risk due to weakened immune systems, an
increased prevalence of underlying comorbidities, and
decreased physiologic reserves to fight infection. Addi-
tionally, elderly patients, especially adults in institutional
settings, are at an increased risk of colonization and sub-
sequent infection with methicillin-resistant Staphylococcus
aureus at a rate that is five times higher than in younger
individuals, causing an increase in empiric and definitive
vancomycin use. Elderly patients have unique character-
istics that make dosing vancomycin a challenge for clini-
cians, such as increased volume of distribution and
decreased renal function. Using the best available evi-
dence, it is recommended to initiate lower empiric main-
tenance doses and monitor vancomycin serum
concentrations earlier than steady state to accurately cal-
culate drug elimination and make appropriate dose
adjustments.
Key Points
Elderly patients are at increased risk for infection,
especially with methicillin-resistant Staphylococcus
aureus.
Debate still exists over how to calculate creatinine
clearance in elderly patients.
Dosing vancomycin is challenging in elderly
patients, and lower empiric maintenance dosing with
earlier concentration monitoring is advised.
1 Introduction
While there has been a shift in leading causes of mortality in
the elderly from infectious diseases to chronic conditions,
infections are still a serious cause of death in this population
[1]. The most common cause of hospitalization in nursing
home patients is infection, and almost 14% of elderly patients
admitted to the hospital are admitted for infection [2]. Infec-
tious diseases-related emergency department visits have been
shown to increase greatly with age among the young-old
(65–74 years), middle-old (75–84 years), and old-old (85?
years) age groups [3]. The highest rate of hospitalizations in
this study occurred in the old-old age group at 66.5%; the
overall hospitalization rate for elderly patients was 57.1%.
Incidence of infection increases as patients age, with the old-
old age group having[30 cases/100,000 persons [4].
In a study by Solis-Hernandez et al., which compared
hospital-acquired infections in the elderly (65? years) versus
younger patients, the elderly population demonstrated a sta-
tistically significant increase in acquisition of ventilator-as-
sociated pneumonia, secondary bacteremia, and catheter-
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associated urinary tract infections (UTIs) [5]. The elderly
patients in this study also experienced similar rates of hospital-
acquired pneumonia, primary bacteremia, catheter-related
bloodstream infections, UTIs, surgical site infections, and
skin and soft tissue infections (SSTIs). Methicillin-resistant
Staphylococcus aureus (MRSA) is often suspected in these
hospital-acquired infections. The drug of choice to provide
empiric antibiotic coverage of MRSA in these infections is
frequently vancomycin.
Vancomycin is a glycopeptide antibiotic first discovered
in the 1950s and approved by the FDA in 1958 [6]. It has
slowly bactericidal activity against Gram-positive organ-
isms such as Staphylococcus aureus and pneumococci, and
bacteriostatic activity against enterococci [7, 8]. Van-
comycin also has activity against Clostridium difficile [7].
Early on, toxicity fears limited the uptake of vancomycin in
favor of emerging semi-synthetic penicillins and cephalos-
porins [6]. Toxicities associated with vancomycin include
infusion-related reactions (including red man syndrome),
nephrotoxicity, and ototoxicity. Purification of vancomycin
over the years has resulted in fewer toxicities. Use of van-
comycin greatly increased in the 1980s and 1990s, with the
emergence of MRSA. Currently, vancomycin is one of the
primary antibiotics used to treat complicated infections
suspected to be caused by MRSA, including nosocomial
infections [8]. According to the guidelines set forth by the
Infectious Diseases Society of America (IDSA), in patients
with normal renal function, a vancomycin dose of 15–20 mg/
kg of actual body weight every 8–12 h is recommended, not
to exceed 2 g per dose [9]. In critically ill patients, a loading
dose of 25–30 mg/kg may be considered. In patients with
compromised renal function, dosing intervals should be
extended to every 24 h or greater. Serum trough concentra-
tions should be monitored prior to the fourth dose (approx-
imate steady-state concentration). Goal trough values
depend on the source of infection; for serious infections,
troughs of 15–20 lg/mL should be targeted [8]. IDSA
guidelines recommend vancomycin as first-line therapy for
complicated SSTIs, bacteremia, infective endocarditis,
pneumonia, osteomyelitis, septic arthritis, meningitis, and
abscesses [8]. While the guidelines provide dosing recom-
mendations specific for the pediatric population, there are no
recommendations specific for the geriatric population, other
than dosing based an individual’s creatinine clearance.
2 Pharmacokinetic and Pharmacodynamic
Considerations in the Elderly
With creatinine clearance representing the only guidance
for vancomycin dosing in the elderly population, it is
important to consider the pharmacokinetic and pharmaco-
dynamic factors that may be altered in these patients.
2.1 Pharmacokinetics
2.1.1 Distribution
There are multiple physiological aspects that can affect the
distribution of drugs, particularly in the elderly, including
the extent of protein binding and total body weight.
Albumin, the most abundant plasma protein that drugs bind
to, can be utilized as a marker for malnutrition. Van-
comycin displays approximately 50% protein binding,
primarily to albumin, in normal, healthy adults [10]. While
age may not be directly correlated to hypoalbuminemia, the
elderly patient population has alterations in taste and smell
which have been associated with geriatric anorexia, ulti-
mately leading to hypoalbuminemia secondary to malnu-
trition [11–14]. In patients 60 years or older, a reduction in
albumin of up to 25% was observed compared with patients
\40 years of age [15]. Furthermore, in the community,
approximately one in ten elderly adults suffers from mal-
nutrition [16]. Conversely, malnutrition rates are high, up
to 61%, in elderly hospitalized patients compared with the
general medicine hospitalized population with rates of
11–44% [17]. An analysis of risk factors for long-term
(C14 days) anti-MRSA therapy identified albumin B2.5 g/
dL as an independent risk factor in a cohort of 71 patients
[18]. A study evaluating the impact of albumin on van-
comycin in patients 75 years or older with MRSA pneu-
monia demonstrated worse clinical outcomes for patients
with severe (\2.5 g/dL) versus non-severe hypoalbumine-
mia [19]. Severe hypoalbuminemia was associated with
increased 28-day mortality, and nephrotoxicity was asso-
ciated with an increase in vancomycin half-life. However,
it is important to note that these patients had higher
severity of infection at baseline.
Total body weight also affects the volume of distribu-
tion. Irrespective of age, obesity (BMI C30) rates continue
to rise over time in the United States [20]. In the elderly
specifically, rates of obesity differ based upon age classi-
fication. In the young-old (65–74 years of age) population,
obesity rates are highest at 40.8%, affecting over 8 million
US adults [20]. Fortunately, this number decreases dra-
matically to 27.8% in the middle- and old-old populations.
Patient weight is an important characteristic when consid-
ering vancomycin dosing because total body weight is
directly correlated to volume of distribution of this agent
[21, 22]. Pending weight status, over- or under-dosing of
vancomycin could easily occur.
2.1.2 Metabolism
Vancomycin does not undergo apparent metabolism;
therefore, age would not likely affect this pharmacokinetic
parameter.
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2.1.3 Excretion/Elimination
With renal function being the primary route of elimination
for intravenous vancomycin, changes related to aging are
an important consideration. Although the half-life (t) of
vancomycin is 4–6 h in healthy subjects with normal renal
function [10], decreased renal function has repeatedly
demonstrated an inverse correlation to elimination half-life
[23–28]. In an evaluation of 288 hospitalized patients (148
elderly, 140 young) receiving vancomycin therapy, the
mean t observed was 17.8 versus 7.5 h, respectively [29].
Without dosage adjustments, there is an increased risk of
vancomycin-induced nephrotoxicity in the elderly popula-
tion due to prolonged t, likely attributable to decreased
renal function.
2.2 Pharmacodynamics
Comparable with the non-elderly population, the pharma-
codynamic parameter that best correlates with efficacy for
vancomycin is the ratio of the 24-h area under the con-
centration–time curve and minimum inhibitory concentra-
tion (AUC0–24/MIC) [9, 30]. While an AUC/MIC[400 has
been established as the number needed for treatment effi-
cacy [31], emerging data suggests that an AUC/MIC of
C521 for dose 1 and C650 for dose 2 are more accurate at
maintaining treatment efficacy [32]. Despite the AUC/MIC
more closely associating with clinical success than serum
trough concentrations, it is rarely calculated due to per-
ceived difficulty for bedside clinicians [31, 33]. Therefore,
vancomycin serum trough concentrations of 15–20 lg/mL
are utilized as a surrogate marker for clinical success
[34, 35]. Unfortunately, clinical failure, including mortal-
ity, is more likely when the MRSA MIC values to van-
comycin are[1 lg/mL due to the inability to achieve the
appropriate AUC/MIC target [36–38]. Despite numerous
reports demonstrating this finding, one meta-analysis
assessing the association between vancomycin MIC and
mortality in patients with S. aureus bacteremia did not find
a mortality association [39]. The authors of this study
concluded that clinicians should ensure that patients are
evaluated for proper source control and treated for an
appropriate duration regardless of vancomycin MIC values.
Conversely, other studies have demonstrated that treatment
failure is more likely for organisms with vancomycin MICs
[1 lg/mL, even when agents other than vancomycin are
utilized, suggesting that these strains may have increased
virulence when compared with strains with lower MICs
[40–42]. Therefore, in instances in which there is an isolate
with an elevated vancomycin MIC ([1 lg/mL), van-
comycin should be avoided.
3 Key Clinical Issues
3.1 Identifying Infections
Elderly adults continue to be at high risk for infections,
leading to greater complications and subsequent mortality,
than younger counterparts [43–45]. Some factors that
contribute to this increased risk include weakened immune
systems, increased prevalence of underlying comorbidities,
increased amount of diagnostic and invasive procedures,
and decreased physiologic reserves to fight infection
[43, 44]. The most common infections in elderly adults
tend to be respiratory tract infections, UTIs, abdominal
infections, and SSTIs [44]. Respiratory tract infections,
specifically pneumonia, are the eighth leading cause of
death in the US [46], with close to 90% of these occurring
in adults 65 years of age and older [43]. Especially con-
cerning is the lack of classic clinical manifestations in
elderly adults. These patients may present with weakness,
confusion, or urinary incontinence [44], instead of tradi-
tional signs such as fever and leukocytosis. Additionally,
elderly patients, especially adults in institutional settings,
are at an increased risk of colonization and subsequent
infection with MRSA [43, 45, 47] at a rate that is five times
higher than in younger individuals [48]. It is important to
recognize these non-traditional signs of infection to be able
to adequately care for this population.
3.2 Estimating Renal Function and Dosing
Vancomycin
Renal function declines with age due to functional and
structural changes [49], and dosage adjustments for renal
function are a necessity. Elderly patients represent a
heterogeneous population [50], thus making it difficult to
accurately estimate their renal function. Studies have
examined several equations in an attempt to elucidate an
accurate estimate of renal function: the Cockcroft–Gault
(CG) method, the Modification of Diet in Renal Disease
(MDRD) method, and the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) method. Each of
these methods is derived from different patient character-
istics, but all only provide estimates of the creatinine
clearance. Elderly patients have characteristics that can
influence interpretation and use of these equations, such as
increased comorbidities, decreased nutritional status, and
lower body fat to muscle mass composition [51]. Addi-
tionally, many elderly adults may have decreased muscle
mass, which also leads to lower serum creatinine [49, 52].
However, they also can have serum creatinine values
within the normal limits but still have reduced renal
function [53]. If a lower serum creatinine value is utilized
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to estimate renal function, this can result in overestimation
of doses required for renally eliminated drugs, thus con-
tributing to drug overdose and toxicity [54]. This has led
many clinicians to compensate for a low serum creatinine
by rounding up to 1 mg/dL; however, this practice has not
been validated and is not encouraged [52, 55]. A study by
Roberts et al. examined the differences between the MDRD
equation, the traditional CG equation, and an optimized CG
equation in determining which provided a more accurate
assessment of renal function in elderly patients to adjust
drug doses [54]. The optimized CG equation differs from
the traditional CG equation by utilizing the lesser of actual
body weight or ideal body weight and capping the serum
creatinine at a minimum of 0.68 mg/dL, instead of 1 mg/
dL. Additionally, the authors measured creatinine values
using assays that were aligned with the isotope dilution-
mass spectrometry (IDMS) method to be able to stan-
dardize their results. The authors found that the traditional
CG equation overestimated renal function, the optimized
CG equation underestimated renal function by 10%, and
the MDRD equation overestimated renal function by 29%.
They concluded that the optimized CG equation was the
most appropriate of the three equations examined to dose
renally eliminated drugs. Conversely, a study by Tsuji et al.
found that if the serum creatinine is measured using the
Jaffe method, instead of the IDMS method, then a cor-
rection of serum creatinine to 0.68 mg/dL is unnecessary
within the CG equation [56]. Additionally, a study by
Glatard et al. found that the CG equation, MDRD equation,
and CKD-EPI equations are not interchangeable when
calculating vancomycin dosing and prediction of concen-
trations based on renal function [57]. The authors con-
cluded that whichever equation clinicians utilize to
calculate renal function should be the same equation used
to dose renally eliminated drugs.
As vancomycin is approximately 90% renally elimi-
nated unchanged in the urine [56, 57], it is imperative to
accurately estimate renal function when calculating dosing
regimens to help optimize the pharmacokinetic and phar-
macodynamic properties of the drug. Cutler et al. compared
vancomycin kinetics in younger patients (mean age: 23
years) versus older patients (mean age: 68 years) [58].
They concluded that there was a significant difference in
vancomycin distribution between younger patients (0.64 L/
kg) and older patients (0.93 L/kg) that is not attributable to
protein binding, but rather to greater tissue binding. Fur-
thermore, the authors found that the vancomycin half-life
was shorter in younger patients (7.2 h) than in elderly
patients (12.1 h), which was attributable to the enlarged
distribution (44% higher than in younger patients) and
reduced clearance (23% lower than in younger patients).
Another study by Sa´nchez et al. also found elderly patients
to have an expanded volume of distribution and a reduced
clearance than younger patients [59]. Hence, when deter-
mining dosing frequency, it is vital to account for the
volume of distribution, target trough, elimination rate, and
duration of therapy. The target trough range for van-
comycin is anywhere between 10 and 20 lg/mL, depend-
ing on the site of infection. In elderly adults, it is
recommended to utilize lower empiric maintenance doses
of vancomycin to compensate for the reduced clearance
secondary to enhanced tissue binding and reduced overall
systemic and renal clearance [44, 58]. Increased duration of
vancomycin therapy has been linked to the development of
nephrotoxicity; therefore, close monitoring of vancomycin
concentrations and renal function is highly recommended
in elderly patients [60].
Elderly patients who are critically ill represent a unique
challenge when dosing vancomycin, not only due to altered
pharmacodynamics, but also because of a paucity of data
available. A recent study by Shahrami et al. examined the
impact of early individualized dosing of vancomycin in
critically ill patients (mean age: 48 years) compared with
standard monitoring [61]. They concluded that by moni-
toring serum concentrations of vancomycin obtained after
the first dose, and again 4–6 h later, more patients were
able to achieve goal peak and trough steady-state concen-
trations. While more data is needed to validate these
findings, this study represents a valid option for pursuing
optimization of vancomycin therapy in critically ill
patients.
Another vancomycin optimization concept that has been
introduced in recent years is continuous infusion. The
intent of continuous infusion is to reduce toxicity, achieve
target concentrations quicker, and avoid treatment failure
[62]. Several studies have examined the impact of contin-
uous infusion vancomycin in critically ill patients with
mixed results. Saugel et al. conducted a prospective,
observational study evaluating a dosing algorithm for
continuous vancomycin administration in critically ill
patients [63]. They found that continuous infusion of
vancomycin allowed for rapid achievement of target serum
concentrations but that these concentrations often became
supratherapeutic. Blot et al. examined 42 patients in 26
different intensive care units (ICUs) from the Defining
Antibiotic Levels in Intensive Care (DALI) study to
determine if contemporary vancomycin dosing results in a
favorable response [64]. They identified that while con-
tinuous infusion of vancomycin was able to attain clinically
relevant trough concentrations and pharmacodynamic
exposure, there was significant variation within the popu-
lation, and the benefits of continuous infusion were not
retained in multivariate analysis. When examining clinical
outcomes of continuous infusion, Tafelski et al. found that
while target serum vancomycin concentrations were
achieved 1 day earlier in continuous infusion versus
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intermittent infusion, there were no significant differences
in ICU mortality rate, duration of ICU stay, and duration of
mechanical ventilation between groups [62].
While trying to achieve pharmacodynamic targets for
vancomycin administration, clinicians also need to balance
the incidence of nephrotoxicity. A study by Cianferoni
et al. examined the incidence of nephrotoxicity in 207
critically ill patients receiving continuous-infusion van-
comycin [65]. The authors concluded that 25% of the
included patients developed acute kidney injury, which was
predicted by the magnitude of vancomycin serum con-
centrations and duration of vancomycin therapy. Another
study by Hanrahan et al. examined the incidence of
nephrotoxicity and death based on continuous versus
intermittent vancomycin infusion strategies [66]. The
authors also found that the incidence of nephrotoxicity was
related to the magnitude of vancomycin serum concentra-
tions and duration of vancomycin therapy. While there
were numerically more patients in the continuous infusion
group that developed nephrotoxicity than in the intermit-
tent infusion group (54 vs 26%), a multivariate regression
model indicated that intermittent infusion, among other
factors, was an independent predictor of the development
of nephrotoxicity. The authors also concluded that despite
having a higher incidence of death within 72 h of the last
vancomycin dose in the continuous infusion group com-
pared with the intermittent infusion group (20 vs 9%), there
was no statistically significant difference in mortality.
Overall, controversy still remains as to the clinical efficacy
and utility of employing continuous infusion vancomycin
in critically ill patients. Additionally, the studies mentioned
above did not examine the impact of continuous infusion
vancomycin in elderly critically ill patients, making the
generalization to this population difficult.
3.3 Vancomycin Monitoring and Infection
Resolution
When utilizing vancomycin, it is important to ensure safe
and effective concentrations of the drug. Vancomycin has
been shown to have a prolonged half-life in elderly patients
compared with younger patients, as well as a larger volume
of distribution and decreased clearance, which are all fac-
tors that can contribute to vancomycin accumulation
[56–58]. With accumulation of vancomycin comes the risk
for its most concerning side effect, which is the incidence
of nephrotoxicity. Current estimates of vancomycin-in-
duced nephrotoxicity range anywhere from 5 to 35% [60],
with some sources citing a specific incidence of 31–34% in
patients 65 years of age and older [67]. As previously
discussed, the compromised renal function found in elderly
patients often puts them at increased risk of developing
nephrotoxicity due to vancomycin [60]; however, there are
also data that suggest that increased age alone (in the
absence of other complications) is not a risk factor for
vancomycin-induced nephrotoxicity [67].
Once adequate therapy has been prescribed, it is
important to monitor for signs of resolving infection.
Elderly patients tend to have greater complications from
infections, leading to increased morbidity and mortality
[44]. Additionally, the goal may not always be to return
elderly patients to a normal functioning state, but rather, to
return them to their baseline functional status. Thus, it is
extremely important to identify what the end goal of
therapy needs to be for these patients.
4 Practical Applications
While dosing of vancomycin should be individualized for
each patient, there is a general thought process for
healthcare providers when dosing vancomycin in elderly
patients (Fig. 1).
4.1 Dosing
When dosing vancomycin in elderly patients, one should
consider the entire patient. What is the body mass com-
position? Is the patient frail or healthy? Patients who are
healthy, especially in the young-old and sometimes in the
middle-old subsets, often can be initiated on treatment
dosages the same as in a younger adult (15–20 mg/kg with
frequency dependent on renal function) [9]. As patients
become frail, lose muscle mass, or approach the old-old
subset, alterations in the dosage or dosing frequency may
be necessary regardless of age or laboratory values.
For elderly patients who are not as healthy as younger
adults, consideration should be given to a reduction in
maintenance dosing. Vancomycin is highly lipophilic and
distributes well into tissue, including fat [10]. Accordingly,
patients with less body fat may concentrate vancomycin
more rapidly in the blood stream, potentially leading to a
higher risk of toxicity secondary to accumulation. In
patients who are frail or thin, loading doses should still be
initiated at 25–30 mg/kg based on actual body weight,
especially if the actual body weight is less than the ideal
body weight, in patients with severe infections from sus-
pected MRSA [9]. If practicing at an institution that rounds
vancomycin doses for ease of preparation, consideration
should be given to rounding down to the nearest increment
instead of rounding up, depending on severity of illness.
Maintenance doses may be empirically reduced (one study
suggested 10 mg/kg) and frequency adjusted for renal
function in these patients [68].
Similarly, patients in the middle-old or old-old subset
who are obese may also need altered dosing regimens
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[69, 70]. In these patients, loading doses of 15–25 mg/kg
should be based on actual body weight [71]. Because
vancomycin accumulates in the tissues [58, 72], consider-
ation should be given to empirically reducing the mainte-
nance dose, particularly in patients who are critically ill
[9, 29, 68, 70]. Additionally, even though vancomycin is
50% bound to serum albumin [10], clinically dosing van-
comycin according to serum albumin concentrations is not
performed. Conversely, it is important to remember that
elderly patients with low albumin are at risk for longer
vancomycin therapy [18]. Furthermore, elderly patients
with MRSA pneumonia also have the potential to have
worse clinical outcomes despite adequate vancomycin
therapy, in part due to low albumin [19]. Therefore, if
practicing at an institution that utilizes loading doses,
consider a lower empiric maintenance dose to account for
the serum accumulation over time, while still adjusting
further maintenance dosing by utilizing serum concentra-
tions or calculated AUC/MIC ratio of vancomycin
[29, 68, 73].
Regardless of weight, clinicians should carefully con-
sider age-related changes in kidney function, including loss
of 20–25% of renal mass and 20–30% of glomeruli com-
pared with younger patients [74]. In addition to renal
changes, muscle mass often decreases with increasing age
[75]. This can impact laboratory values such as serum
creatinine, ultimately impacting common calculations used
to estimate creatinine clearance (such as the CG equation)
[75, 76]. In patients with muscle tone similar to a younger
adult, frequency of vancomycin should follow recom-
mendations based on estimated glomerular filtration rate
[10]. In frail patients or those with reduced muscle mass or
suspected reductions in renal function, clinicians may
consider adjustments for very low serum creatinine values
(\0.5 mg/dL), possibly including rounding to a higher
value (0.68 mg/dL) in order to more accurately estimate
creatinine clearance [54]. Because renal function is often
decreased in elderly patients [77, 78], particularly the old-
old subset, consideration should be given to empirically
beginning these patients with daily administration instead
Fig. 1 Steps to consider when dosing vancomycin in elderly patients. AUC/MIC the ratio of the 24-h area under the concentration–time curve
and minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus
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of twice daily administration, regardless of estimated cre-
atinine clearance.
4.2 Determination of Response
Irrespective of dosing strategy used, elderly patients should
be monitored for evidence of response, including both
efficacy and toxicity. In patients with stable renal function,
vancomycin serum trough concentrations should be moni-
tored just prior to the fourth dose for short courses, and
adjustments made accordingly [9]. For longer courses,
clinicians may choose to monitor routinely as deemed
clinically appropriate [9]. Clinically, patients with
stable renal function on prolonged courses are monitored
approximately once per week. Goal trough concentrations
for adults are generally between 15 and 20 lg/mL, but may
be higher or lower depending on infection, severity of ill-
ness, and clinical judgement [9]. In the elderly, new evi-
dence suggests that troughs[15 lg/mL are associated with
increased rates of nephrotoxicity, and should not be
exceeded [79]. Clinicians should monitor elderly patients
carefully, possibly accepting a lower trough concentration
if clinical improvement is seen.
In patients with fluctuating or rapidly changing renal
function, clinicians should consider monitoring serum
concentrations sooner than the fourth dose or more fre-
quently [61]. If the trough concentration is drawn prior to
the fourth dose, concentrations above the desired range
likely signify potential for toxicity and may represent a
need for a lower dose. Low concentrations will not be
representative of the steady-state concentration and should
be addressed using clinical judgement.
In recent literature, it has been suggested that the AUC/
MIC ratio may actually be a better predictor of the phar-
macokinetics of vancomycin [80]. Although AUC/MIC
ratios are not often used clinically because of the difficulty
in calculation, trough concentrations are monitored as a
surrogate for AUC/MIC ratio [9]. However, data by Pai
et al. has demonstrated that single trough concentrations
are not sufficient to aid clinicians in effectively dosing
vancomycin [32]. The authors recommended two different
approaches to monitoring vancomycin: Bayesian and
equation-based. Bedside software programs are available
for clinicians to be able to perform Bayesian modeling for
patients on vancomycin, thus personalizing the patient’s
care. Alternatively, equation-based monitoring can be
programmed into the electronic medical system to auto-
matically calculate the patient’s daily vancomycin AUC.
Additionally, new evidence suggests that specific AUC/
MIC goals may be better clinical markers of therapeutic
efficacy [73]. In the general adult population, AUC/MIC
ratio of [400 lg h/mL is targeted to provide effective
therapy should the MRSA isolate have a vancomycin MIC
B1 [9]; alternatively, the new proposed AUC/MIC targets
of C521 on day 1 and C650 on day 2 should be sufficient
for a 80–85% clinical success rate [36]. In the elderly
population, a targeted AUC/MIC of 250–450 lg h/mL
may provide improved efficacy while limiting toxicity
[73]. Ultimately, the decision on how to monitor van-
comycin and adjust doses lies with the clinician.
In addition to serum concentrations, clinicians should
monitor for clinical resolution of infection or improvement
in systemic symptoms (resolution of fever, normalization
of white blood cell count, improvement in inflammatory
biomarkers) in order to determine clinical response. If it is
determined that the patient is not responding clinically after
a sufficient trial of appropriately dosed vancomycin (ap-
propriate trough concentrations for 5–7 days, depending on
infection location and severity), consideration should be
given to adjusting the dose or choosing an alternative
treatment regimen.
5 Conclusions
Elderly patients have many physiologic changes that occur
that put them at increased risk for infection, renally
adjusted dosing miscalculations, and adverse drug reac-
tions. It is important to remember that the volume of dis-
tribution increases, serum creatinine may decrease,
increase, or remain constant, and creatinine clearance
decreases in elderly patients. Loading doses remain con-
sistent with recommendations for all patient ages, while
lower maintenance doses and frequencies are recom-
mended specifically in elderly patients. Monitoring of
vancomycin concentrations earlier than steady state, as
well as continued monitoring using either Bayesian fore-
casting or equation-based approaches should be considered
for this patient population. Clinicians should understand
the physiologic changes that occur, particularly when uti-
lizing vancomycin to treat elderly patients with suspected
or documented Gram-positive infections, in order to safely
and effectively treat this patient population. Overall,
elderly patients represent a heterogeneous group that
should be treated individually and monitored closely.
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